Search

Introduction: Hypofractionation (HF) in breast cancer is a radiotherapy regimen frequently used in recent years. Greater toxicity has been described in irradiated patients with heterologous breast reconstruction procedures, but it is unknown if this greater toxicity could be avoided by using hypofractionated intensity modulated radiotherapy (IMRT). The objective of this study is to describe the toxicity and complications presented in breast cancer patients that were reconstructed with a tissue expander (EXP) treated with IMRT and to determine if there are differences according to the used fractionation regimen. Method: All patients with breast cancer reconstructed with expander and treated with adjuvant IMRT to the chest wall and regional lymph nodes were included, using conventional fractionation (CF) dose of 50 Gy in 25 fractions or hypofractionated (HF) regimen dose of 45 Gy in 20 fractions. Acute and late toxicity, during treatment and at the end of follow-up, were recorded according to RTOG / EORTC and CTCAE 4.0 criteria and the BREAST Q 2.0 quality of life survey postoperative reconstruction module (QoL) was applied in the last follow-up visit. Results: 33 patients were analyzed. With a median follow-up of 17 months, 31 were treated with Tomotherapy and 2 with VMAT. CF was used in 20 and HF in 13. There was no G3 acute toxicity, and G2 was observed in only 1 patient with HF (7.6%) and in 3 with CF (15%), mainly determined by radiodermatitis. Regarding late toxicity (LT), there was only one G3 event which occurred in a patient with CF and full axillary irradiation. Grade 2 LT was not observed in patients treated with HF, whereas with CF 2 cases (10%) were reported. During the expander period, 1 patient with HF presented a complication (7,6%) and 3 with CF (15%), 2 of the latter required unscheduled surgical intervention (USI). 12 patients in the HF group underwent prosthetic replacement (92%) and 15 in the CF group (75%). After the replacement 4 patients with CF required an USI (26.6%) and none of the patients in the HF group had post replacement complications that required hospitalization. None of the previously mentioned differences were statistically significant. Regarding QoL, the patients with HF had a better late toxicity score, with an average of 96.7 vs. 82.4 points (p Citation Format: Ariel Fariña, Dagmar Alfonso, Aroldo Fernandez, Felipe Carvajal, Ana María Ciudad, Celmira Martínez, Camila Pérez, Pablo González, Hugo Marsiglia. Hypofractionated versus conventional intensity modulated postmastectomy radiotherapy: Toxicity and quality of life in patients with tissue-expander breast reconstruction [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS15-17.

Glioblastoma (GB) is the most frequent and aggressive primary tumor of the central nervous system (CNS) in adults. Standard treatment is complete tumor resection followed by concomitant radiochemotherapy (RCT) and subsequent adjuvant temozolomide (TMZ). Information about brain tumors statistics in Latin American countries is scarce, so we aimed to measure the overall survival (OS) of patients with resected GB in a single institution in Chile. This is a retrospective report of 67 patients treated between 2012 and 2019 with resected GB and who received adjuvant treatment with radiotherapy (RT) with and without TMZ during 2012-2019 in this center (Chilean NCI). Most of them were men (72%), ages > 50 years old (57%), with Karnofsky performance status (KPS) scale ≥ 70% (94%) and recursive partitioning analysis-IV (RPA-IV) (60%). Some 54% received concomitant TMZ and RT. Median OS was 11.4 months, with 1-, 2-, and 5-year OS of 48%,15%, and 3% respectively. In conclusion, in patients with GB treated with RCT at the NCI, OS was the same as expected from international articles. Adjuvant RCT therefore is considered the standard of care at NCI.

BACKGROUND: The present study was a prospective observational study to evaluate the safety profile of Celtura((R)), a monovalent, cell culture-derived, inactivated subunit influenza vaccine prepared from A/California/07/2009(H1N1) with the adjuvant MF59((R)). Subjects were enrolled prospectively during the H1N1 2009 influenza pandemic at medical centres in Colombia, Chile, Switzerland, and Germany during the period December 2009 to June 2010. METHODS: Subjects ages 18 and older were followed for the occurrence of adverse events (AEs) for six months after vaccination. Adverse events of special interest (AESIs) were neuritis, convulsion (seizure), anaphylaxis, encephalitis, vasculitis, Guillain-Barre syndrome, demyelinating conditions, Bell's palsy, and laboratory-confirmed vaccination failure. RESULTS: Overall, 7348 AEs were reported in 2296 of 3989 enrolled subjects (57.6%). Only two AEs were considered related to injection site reactions. No laboratory-confirmed cases of influenza were reported. There were 108 medically confirmed serious adverse events (SAEs) reported among 73 subjects with 6 such SAEs described as possibly or probably related to vaccination. Three fatal cases were reported and assessed as not related to vaccination. Two AESIs classified as convulsion were reported and assessed as not related to vaccination. Both AESIs occurred well outside the pre-specified 7 day risk window representing the likely timeframe of the occurrence of seizure following vaccination. CONCLUSIONS: The results of this study support the overall good safety profile of MF59 adjuvanted cell culture-derived influenza vaccine as administered in adults during the 2009-2010 H1N1 influenza pandemic. No concern is raised regarding the occurrence of AESIs